Inhibition of tumor growth by histoincompatible cells expressing interleukin-2.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  International Immunology

• Publication date

  1992-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/INTIMM/4.12.1429PMID 1286066
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• rIL-4 differentially regulates rIL-2-induced murine NK and LAK killing in CD8+ and CD8- precursor cell subsets.

  1991cited by this paper
• Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.

  1991cited by this paper
• Interleukin 2‐dependent activation of tumor‐specific cytotoxic T lymphocytes in vivo

  1991cited by this paper
• Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2.

  1990cited by this paper
• Cloning of an interleukin-4 inducible gene from cytotoxic T lymphocytes and its identification as a lipase.

  1990cited by this paper
• Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity

  1990cited by this paper
• Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response.

  1990cited by this paper
• A novel approach to the induction of specific cytolytic T cells in vivo.

  1990cited by this paper
• Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action

  1990cited by this paper
• Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity.

  1990cited by this paper
• Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy.

  1990cited by this paper
• IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.

  1989cited by this paper
• Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity.

  1989cited by this paper
• Derivation of a T cell line that is highly responsive to IL-4 and IL-2 (CT.4R) and of an IL-2 hyporesponsive mutant of that line (CT.4S).

  1989cited by this paper
• Murine interleukin-4 displays potent anti-tumor activity in vivo.

  1989cited by this paper
• Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors

  1988cited by this paper
• Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors.

  1988cited by this paper
• The effects of IL-4 on human natural killer cells. A potent regulator of IL-2 activation and proliferation.

  1988cited by this paper
• Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice.

  1988cited by this paper
• Interleukin 4 (IgG1 induction factor): a multifunctional lymphokine acting also on T cells

  1987cited by this paper
• Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes.

  1986cited by this paper
• The NK-1.1(-) mouse: a model to study differentiation of murine NK cells.

  1986cited by this paper
• Establishment of Monoclonal Anti-Nk-1.1 Antibody

  1984cited by this paper
• Growth inhibition of a MC-induced mouse sarcoma by TCGF (IL 2)-containing preparations

  1983cited by this paper
• Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2

  1982cited by this paper
• Establishment of a calcitonin-producing rat medullary thyroid carcinoma cell line. I. Morphological studies of the tumor and cells in culture.

  1980cited by this paper
• In vitro NK‐activity and in vivo resistance to leukemia: Studies of beige, beige/nude and wild‐type hosts on C57BL background

  1980cited by this paper
• Monoclonal cytolytic T-cell lines

  1979cited by this paper
• Regional differences in the incidence and growth of mouse tumors following intradermal or subcutaneous inoculation.

  1978cited by this paper
• „Natural”︁ killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype

  1975cited by this paper
• Transplantable calcitonin-secreting medullary carcinomas of the thyroid in the WAG-Rij rat.

  1974cited by this paper
• Studies in a tumor spectrum. III. The effect of phosphoramides on the growth of a variety of mouse and rat tumors.

  1955cited by this paper

• Development of an attenuated interleukin‐2 fusion protein that can be activated by tumour‐expressed proteases

  2011cites this paper
• Klonieren der felinen Zytokin-Gene IL-2, GM-CSF und IFNg zum adjuvanten, nonviralen gentherapeutischen Einsatz beim Fibrosarkom der Katze

  2005cites this paper
• Antineoplastic activity of alkylphosphocholines (APC) in human breast carcinomasin vivo andin vitro; use of liposomes

  2004cites this paper
• Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: Phase II randomized study comparing two dose levels

  2002cites this paper
• Enhancement of anti-tumour immunity by transduction with a Mycobacterium tuberculosis gene.

  2001cites this paper
• Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings

  2000influential citation
• The basis of electrochemotherapy.

  2000cites this paper
• Mechanisms of electrochemotherapy.

  1999cites this paper
• Gene therapy study of cytokine-transfected xenogeneic cells (Vero-interleukin-2) in patients with metastatic solid tumors

  1999cites this paper
• Receptor-mediated interleukin-2 gene transfer into human hepatoma cells.

  1999cites this paper
• Cancer gene and immunotherapy: recent developments

  1999cites this paper
• Gene therapy with cytokine-transfected xenogenic cells (Vero-IL-2) in patients with metastatic solid tumors: mechanism(s) of elimination of the transgene-carrying cells

  1999cites this paper
• Treatment of medullary thyroid carcinoma by combined expression of suicide and interleukin-2 genes

  1999cites this paper
• Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model.

  1998cites this paper
• Gene therapy with cytokine-transfected xenogeneic cells in metastatic tumors.

  1998cites this paper
• Antimetastatic effects of electrochemotherapy and of histoincompatible interleukin‐2-secreting cells in the murine Lewis lung tumor

  1998cites this paper
• IL-10 gene transfer to intracranial 9L glioma: tumor inhibition and cooperation with IL-2.

  1998cites this paper
• Cancer immunotherapy by direct in vivo transfer of immunomodulatory genes.

  1998cites this paper
• Tumor immunotherapy by vaccination with cytokine gene transfected cells.

  1997cites this paper
• Immunostimulatory cytokines in somatic cells and gene therapy of cancer.

  1997cites this paper
• IL-2 gene delivery within an established murine tumor causes its regression without proliferation of preexisting antitumor-specific CTL.

  1997cites this paper
• First clinical trial of cat soft-tissue sarcomas treatment by electrochemotherapy.

  1997cites this paper
• Treatment of transplanted spontaneous rat T-cell leukaemia with local administration of recombinant murine interleukin-2.

  1997cites this paper
• Interleukin-2 (IL-2) gene therapy with allogeneic fibroblasts in the CT-26 model of murine colorectal carcinoma.

  1997cites this paper
• Host's immune response in electrotherapy of murine tumors by direct current.

  1997cites this paper
• In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector.

  1996cites this paper
• Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism

  1996cites this paper
• Gene therapy of spontaneous canine melanoma and feline fibrosarcoma by intratumoral administration of histoincompatible cells expressing human interleukin-2.

  1996cites this paper
• LES CYTOKINES ONT 20 ANS : DE LA CULTURE CELLULAIRE AUX APPLICATIONS THERAPEUTIQUES

  1996cites this paper
• Immune response against medullary thyroid carcinoma (MTC) induced by parental and/or interleukin-2-secreting MTC cells in a rat model of human familial medullary thyroid carcinoma

  1996cites this paper
• Antifection: an antibody-mediated method to introduce genes into lymphoid cells in vitro and in vivo.

  1996cites this paper
• IFN-alpha 1 gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice.

  1995cites this paper
• IFN‐α1 gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice

  1995cites this paper
• Cytokine Gene Therapy with Interleukin-2-Transduced Fibroblasts: Effects of IL-2 Dose on Anti-Tumor Immunity

  1995cites this paper
• Comparison of gene therapy with interleukin-2 gene modified fibroblasts and tumor cells in the murine CT-26 model of colorectal carcinoma.

  1995cites this paper
• Local and Systemic Response of Mice to Interferon-α1 -Transfected Friend Leukemia Cells

  1995cites this paper
• Local and systemic response of mice to interferon-alpha 1-transfected Friend leukemia cells.

  1995cites this paper
• Interleukin-2 and interleukin-4 display potent antitumour activity on rat medullary thyroid carcinoma cells.

  1995cites this paper
• Systemic Antitumor Effects of Electrochemotherapy Combined with Histoincompatible Cells Secreting Interleukin‐2

  1995cites this paper
• Experimental gene therapy of cancer using tumor cells engineered to secrete interleukin‐13

  1995cites this paper
• [Antitumoral electrochemotherapy].

  1994cites this paper
• Immune response against tumors.

  1994cites this paper
• [Antitumor electro-chemotherapy].

  1994cites this paper
• Immunoregulation by cytokines.

  1993cites this paper